OKI Yasuhiro | Department of Hematology and Cell Therapy, Aichi Cancer Center
スポンサーリンク
概要
Department of Hematology and Cell Therapy, Aichi Cancer Center | 論文
- Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
- Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
- Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas : Results of a Japanese Phase II Study
- Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
- Phase I Trial of FLAGM with High Doses of Cytosine Arabinoside for Relapsed, Refractory Acute Myeloid Leukemia : Study of the Japan Adult Leukemia Study Group (JALSG)